https://www.selleckchem.com/pr....oducts/zunsemetinib.
6 (95%CI 2.24-10.05), US$91,496 (95%CI 34,700-168,050; p 0.001) for the PHS, both considering adhered and total interventions, respectively. The CP service was not directly cost-benefit at the hospital perspective, but it presented savings for forecast cost related to the occurrence of preventable morbidities, measuring a good cost-benefit for the PHS. The CP service was not directly cost-benefit at the hospital perspective, but it presented savings for forecast cost related to the occurrence of preventable morbidities, measur
Curtir
Comentario
Compartilhar
